Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.


Ozen M., Aksoy S., Dizdar O. , Dede D. S. , Dogan E., Arslan C., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.28, 2010 (SCI İndekslerine Giren Dergi) identifier